Initial treatment of Parkinson's disease

Current Treatment Options in Neurology

Volumn 8, Issue 3, 2006, Pages 224-235

  Tarsy, Daniel ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; NEUROPROTECTIVE AGENT; PERGOLIDE; PETHIDINE; PRAMIPEXOLE; PYRIDOXINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; TRIMETHOPRIM; UBIDECARENONE; UNINDEXED DRUG;

ABDOMINAL PAIN; AGE; AGITATION; AKINESIA; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMA; CONFUSION; CONSTIPATION; DELUSION; DEPRESSION; DIAGNOSTIC TEST; DIARRHEA; DIETARY INTAKE; DISABILITY; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DYSKINESIA; DYSTONIA; EMPLOYMENT; ERYTHROMELALGIA; EXERCISE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INSOMNIA; KINESIOTHERAPY; LABORATORY TEST; LIFESTYLE; LIVEDO RETICULARIS; LIVER TOXICITY; LUNG FIBROSIS; MEDICAL DECISION MAKING; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NEUROIMAGING; NEUROTOXICITY; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL GAMBLING; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PROGNOSIS; PSYCHOSIS; RAYNAUD PHENOMENON; RETROPERITONEAL FIBROSIS; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP DISORDER; SOCIAL SUPPORT; SOMNOLENCE; SPEECH THERAPY; SWEATING; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT PLANNING; TREMOR; URINE RETENTION; VALVULAR HEART DISEASE; VASOSPASM; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

EID: 33645829621     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0013-y     Document Type: Review

References (46)

1. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001, 56(Suppl 5):S1-S88.
2. Tarsy D: Diagnostic criteria for Parkinson's disease. In Parkinson's Disease. Edited by Ebadi M, Pfeiffer R. Boca Raton, FL: CRC Press; 2005:569-578.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
4. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002, 125:861-870.
5. Schults CW, Oakes D, Kieburtz K, et al.: Effects of coenzyme Q10 in early Parkinson disease. Arch Neurol 2002, 59:1541-1550.
6. Goetz CG, Koller WC, Poewe W, et al.: Management of Parkinson's disease: an evidence-based review. Mov Disord 2002, 17(Suppl 4):S156-S159.
7. Ellis T, de Goede CJ, Feldman RG, et al.: Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2005, 86:626-632.
8. Rubinstein PC, Giladi N, Hausdorff JM: The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease. Mov Disord 2002, 17:1148-1160.
9. Cristian A, Katz M, Cutrone E, Walker RH: Evaluation of acupuncture in the treatment of Parkinson's disease: a double-blind pilot study. Mov Disord 2005, 20:1185-1188.
10. Ramig LO, Countryman S, O'Brien C, et al.: Intensive speech treatment for patients with Parkinson's disease: short- and long-term comparison of two techniques. Neurology 1996, 47:1496-1504.
11. Ravina BM, Fagan SE, Hart RG, et al.: Neuroprotective agents for clinical trials in Parkinson's disease. Neurology 2003, 60:1234-1240.
12. Schapira AHV, Olanow CW. Neuroprotection in Parkinson disease. Mysteries, myths, and misconceptions. JAMA 2004, 291:358-364.
13. Ives NJ, Stowe RL, Marro J, et al.: Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomized trials involving 3,525 patients. BMJ 2004, 329:593-596.
14. Waters CH: Fluoxetine and selegiline - lack of significant interaction. Can J Neurol Sci 1994, 21:259-261.
15. Toyana SC, Iacono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994, 28:405.
16. Richard IH, Kurlan R, Tanner C, et al.: Serotonin syndrome and the combined use of deprenyl and an anti-depressant in Parkinson's disease. Neurology 1997, 48:1070-1077.
17. Thorogood M, Armstrong B, Nichols T, Hollowell J: Mortality in people taking selegiline: observational study. BMJ 1998, 317:252-254.
18. Marras C, McDermott NP, Rochon PX et al.: Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohorts. Neurology 2005, 64:87-93.
19. Luginger B, Wenning TK, Bosch S, Poewe W: Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000, 15:873-878.
20. Katzenschlager R, Sampaio C, Costa J, Lees A: Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003, CD003735.
21. Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who have been treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000, 342:1484-1491.
22. Holloway RG, Shoulson I, Fahn S, et al.: Pramipexole vs levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Arch Neurol 2004, 61:1044-1053.
23. Frucht S, Rogers JD, Greene PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole Neurology 1999, 52:1908-1910.
24. Driver-Dunckley E, Samanth A, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003, 61:422-423.
25. Pritchett AM, Morrison JF, Edwards W, et al.: Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002, 77:1280-1286.
26. Parcopa: A rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drug Ther 2005, 47:12.
27. Koller WC, Hutton JT, Tolosa E, et al.: Immediate-relief and controlled-relief carbidopa/levodopa in Parkinson's disease. A five-year randomized multicenter study. Neurology 1999, 53:1012-1019.
28. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37-45.
29. Olanow CW: Oxidation reactions in Parkinson's disease. Neurology 1990, 40(Suppl 3):32-37.
30. Weiner WJ: Initial treatment of Parkinson disease. Levodopa or dopamine agonist. Arch Neurol 2004, 61:1966-1969.
31. Agid Y, Chase T, Marsden CD: Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998, 351:851-852.
32. The Parkinson Study Group: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
33. Olanow CW, Agid Y, Mizuno Y, et al.: Levodopa in Parkinson's disease: Current controversies. Mov Disord 2004, 19:997-1005.
34. Miyasaki J, Martin W, Suchowersky O, et al.: Practice parameter initiation of treatment for Parkinson's disease: an evidence-based review. Neurology 2002, 58:11-17.
35. Nutt JG: Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998, 51:1221-1222.
36. Olanow CW, Kieburtz K, Stern M, et al.: Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004, 61:1563-1568.
37. Olanow CW, Tasmar Advisory Panel: Tolcapone and hepatotoxic effects. Arch Neurol 2000, 57:263-267.
38. Pfeiffer RF, Botis-Wollmer I: Parkinson's Disease and Non-motor Dysfunction. Totowa, NJ: Humana Press; 2005.
39. Hobson DE, Lang AE, Martin WRL: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455-463.
40. Razmy A, Lang AE, Shapiro CN: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004, 61:97-102.
41. Dell'Agnello G, Ceravello R, Nuti A, et al.: SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001, 24:221-227.
42. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease Arch Neurol 2002, 59:1937-1943.
43. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations. Arch Neurol 2005, 62:241-248.
44. Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003, 62:1721-1728.
45. Waters CH, Sethi KD, Hauser RA, et al.: Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a three-month, randomized, placebo-controlled study. Mov Disord 2004, 19:426-432.
46. Elm JJ, Goetz CG, Ravina B, et al.: A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005, 57:197-203.